Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Free Cash Flow (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Free Cash Flow for 6 consecutive years, with -$2.7 million as the latest value for Q4 2021.

  • Quarterly Free Cash Flow fell 24.08% to -$2.7 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was -$11.2 million through Dec 2021, down 3.19% year-over-year, with the annual reading at -$5.2 million for FY2025, 29.89% up from the prior year.
  • Free Cash Flow for Q4 2021 was -$2.7 million at ENDRA Life Sciences, up from -$2.7 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$236274.0 in Q1 2017, with the low at -$3.5 million in Q2 2020.
  • Average Free Cash Flow over 5 years is -$2.1 million, with a median of -$2.1 million recorded in 2020.
  • The sharpest move saw Free Cash Flow plummeted 937.73% in 2018, then increased 18.9% in 2021.
  • Over 5 years, Free Cash Flow stood at -$1.4 million in 2017, then plummeted by 38.3% to -$1.9 million in 2018, then decreased by 2.28% to -$1.9 million in 2019, then fell by 9.87% to -$2.1 million in 2020, then decreased by 24.08% to -$2.7 million in 2021.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$2.7 million, -$2.7 million, and -$2.8 million for Q4 2021, Q3 2021, and Q2 2021 respectively.